We previously conducted a genome-wide linkage analysis of Japanese nuclear families affected with prostate cancer and showed that the susceptibility to prostate cancer was closely linked to D8S550 at 8p23. The role of farnesyl diphosphate farnesyltransferase (FDFT1), which is located under the peak marker D8S550 at 8p23, and squalene synthase, the enzyme encoded by FDFT1, in prostate cancer was studied. METHODS: The association among common variants of FDFT1 with prostate cancer risk, the promoter activities of FDFT1 with different genotypes and the effects of inhibition of squalene synthase were studied, and the FDFT1 transcript levels of human prostate samples were quantified. RESULTS: The A allele of rs2645429 was significantly associated with prostate cancer risk in a Japanese familial prostate cancer population. Rs2645429 was located in the promoter region of FDFT1, and the AA genotype showed significantly increased promoter activity. The knockdown of FDFT1 mRNA expression or squalene synthase inhibition led to a significant decrease in prostate cancer cell proliferation. Additionally, human prostate cancer specimens expressed significantly higher levels of FDFT1 mRNA compared with noncancerous specimens. Finally, aggressive cancers showed higher transcript levels. CONCLUSIONS: FDFT1 and its encoded enzyme, squalene synthase, may play an important role in prostate cancer development and its aggressive phenotypes.
INTRODUCTION
The mortality rate of prostate cancer, which is one of the most common malignancies around the world, is particularly high in Western countries. 1, 2 In comparison, Asian populations have the lowest incidence and mortality rates associated with prostate cancer; however, its incidence is increasing rapidly in Japan and other Asian countries. 3, 4 We have been collecting hereditary/familial prostate cancer (FPC) pedigrees in Japan, and we previously conducted a genomewide linkage analysis of 44 Japanese nuclear families affected with prostate cancer. 5, 6 In that study, we showed that the susceptibility to prostate cancer in Japan was closely linked with D8S550 at 8p23 and D1S2667 at 1p36. Many susceptibility genes for prostate cancer exist, and HPCX and RNASEL have been reported. 7, 8 A genetic linkage study showed an association between familial risk of brain and prostate cancers and the 1p36 chromosome locus. 9 In previous studies on the effects of lipoproteins on prostate cancer proliferation and migration, we found that remnant lipoprotein or high-density lipoprotein exerted proliferative effects on PC-3 and DU-145 prostate cancer cells. 10, 11 Prostate cancer cells express low-density lipoprotein receptor, and downregulation of this protein led to a significant reduction in cell proliferation. 10 Furthermore, we reported that simvastatin inhibited PC-3 cell proliferation via insulin-like growth factor 1 receptor downregulation. 12 The mechanism underlying this effect was related to changes in dolichols that directly affect the N-glycosylation of insulin-like growth factor 1 receptor. 13 Lowdensity lipoprotein receptor and dolichols are closely involved in the mevalonate/isoprenoid pathway. 14 The mevalonate/isoprenoid pathway has two relevant subpathways: the sterol and nonsterol branches. The key enzyme in the sterol branch is squalene synthase, encoded by farnesyl diphosphate farnesyltransferase (FDFT1), which is located under the peak marker D8S550 at 8p23. 15 A previous study showed that FDFT1 is expressed in human prostate cancer cells, that is, LNCaP cells. 16 We also reported FDFT1 expression in PC-3 and LNCaP cells. 17 To our knowledge, the association between FDFT1 genetic polymorphisms and prostate cancer has not been studied. This prompted us to study the relationship between FDFT1 polymorphisms and prostate cancer risk in our FPC pedigrees. We found that a specific genotype of FDFT1 increased the risk of prostate cancer. We also studied the role of squalene synthase in prostate cancer cell proliferation and in the aggressiveness of human prostate cancer.
MATERIALS AND METHODS

Cells and chemicals
LNCaP and PC-3 cells were purchased from Dainippon Pharmaceutical (Tokyo, Japan); COS-1 cells were obtained from Health Science Research Resources Bank (Osaka, Japan). MTS and a Dual-Glo Luciferase kit were obtained from Promega (Madison, WI, USA). The transfection reagent Attractene was purchased from Qiagen (Tokyo, Japan).
Association study on FDFT1 polymorphisms
The present study included probands from 115 families with FPC and 119 patients with BPH as control subjects. All of the subjects were Japanese. Prostate cancer was confirmed histologically at Gunma University Hospital or its affiliated hospitals. The clinical characteristics of the case and control subjects are shown in Table 1 . The patients with FPC ranged in age from 40 to 88 years, with a mean age of 69.1 years. The clinical stage was T1-2N0M0 in 54 patients, T3N0M0 in 31, anyTN1M0 in 4, anyTanyNM1 in 24 and unknown in 2 patients. The unknown stages were primarily because of a lack of bone scan information. The Gleason scores were o7 in 29 patients and X7 in 86. The control subjects were recruited from outpatient clinics at Gunma University Hospital, the most frequent diagnosis being benign prostatic hypertrophy. The controls were excluded if they had an abnormal PSA level (that is, 44.0 ng ml À1 ), an abnormal digital rectal examination or a previous diagnosis of cancer. The controls ranged in age from 51 to 88 years, with a mean age of 71.2 years. No significant difference in age was observed between the cases and controls.
Using information on single-nucleotide polymorphism (SNP) allelic frequencies from the website of the US National Center for Biotechnology Information (NCBI 36; http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi? locusId ¼ 2222) and SNPbrowser software 4.0 (Applied Biosystems, Branchburg, NJ, USA), SNPs in the promoter region, exons and exon--intron junctions of human FDFT1 were surveyed. We selected five common SNPs in FDFT1, as shown in Table 2 . Genomic DNA was isolated from whole blood samples using a Genomix kit (Talent, Trieste, Italy); it was diluted to 10 ng ml À1 and stored at --20 1C. Genotypes were determined using Assayon-Demand kits with the TaqMan SNP Genotyping Assay (Applied Biosystems), as described elsewhere. 18 Reporter assay Vectors containing several human squalene synthase (HSS) promoters and luciferase (pHSS1kb-Luc, pHSS532-Luc and pHSS204-Luc) were used ( Figure 1a) . 19 pHSS1kb-Rev-Luc was constructed as described below. A 1-kb fragment from the full-length promoter of HSS was obtained by a double digest of pHSS1kb-Luc with SmaI and EcoRV. Both enzymes yielded blunt ends, and the backbone vectors and blunt ended 1-kb fragments were ligated. Right-oriented pHSS1kb-Rev-Luc was confirmed by its XbaI digest pattern. To compare promoter activity in the presence of the rs2645429 mutation (located at --195), we made A--G mutations in rs2645429 of pHSS1kb-Luc by mutagenesis (pHSS-mutated). pHSS1kb-Luc and pHSS-mutated had an AA and GG genotype at --195, respectively ( Figure 1b) .
COS-1 or LNCaP cells were transfected at 40--80% confluency using Attractene transfection reagent (Qiagen) according to the manufacturer's instructions. Briefly, cells were seeded in six-well plates at a density of 4 Â 10 5 cells per ml for LNCaP and 2 Â 10 5 cells per ml for COS-1, and then incubated overnight at 37 1C in a 5% CO 2 atmosphere. After 24 h, the medium was removed, and a transfection complex containing 1.2 mg of plasmid DNA, 0.145 mg of pRL-CMV for luciferase analysis normalization and transfection reagent was added to each well in the presence of fetal bovine serum and antibiotics. The transfected cells were incubated for an additional 24 h and then lysed and assayed. Photinus and Renilla luciferase activity was measured using the DualLuciferase Reporter Assay System (Promega) with a luminometer (Wallac 1420 ALVOmx; PerkinElmer, Waltham, MA, USA). Photinus luciferase activity was normalized to Renilla luciferase activity to calculate the relative reporter activity for each construct. The results from three independent experiments were plotted, with each assay conducted in triplicate. 
Proliferation assay
We performed an MTS proliferation assay of LNCaP and PC-3 cells with small interfering RNA (siRNA) targeting FDFT1 or the squalene synthase inhibitor TAK-475. Using 96-well plates, cells were transfected with FDFT1 siRNA or treated with various concentrations (0, 1, 10, 30 and 100 mM) of TAK-475, 20 and then incubated for 48 h to evaluate the effect on cell proliferation. The siRNA transfection procedures using Oligofectamine (Invitrogen, Carlsbad, CA, USA) were as described previously. 21 Three different siRNA oligonucleotides targeting FDFT1 were used. The target sequences of siRNA oligonucleotides were 5 0 -CACCATAAAGTGGATTTAC TT-3 0 (Hs_FDFT1_2, SI00064071, QIAGEN), 5 0 -TCCTACTACTTTAATCCCTAA-3 0 (Hs_FDFT1_5, SI02633323) and 5 0 -CTGGCGGTTCATGGAGAGCAA-3 0 (Hs_ FDFT1_8, SI03098221, QIAGEN). For negative siRNA control, a scrambled RNA was used (No. 1022076, QIAGEN). Total RNA extraction and complementary DNA synthesis were performed as described elsewhere. 21 Transcript levels were quantified using an iCycler iQ (Bio-Rad, Hercules, CA, USA) according to the manufacturer's instructions. Amplification was conducted in 10 ml of Premix Ex Taq using 2 ml of complementary DNA and FDFT1 primers (forward, 5 0 -GGTCCCGCTGTTACACAACT-3 0 and reverse, 5 0 -AAAACTCTGCCAATGCCCA-3 0 ). PCR was performed with one cycle of 10 min at 95 1C, followed by 40 cycles of 15 s at 95 1C and 60 s at 60 1C. For standard curve generation and the internal control, b-actin transcript levels were used, as described elsewhere. 21 Cell viability at 48 h was measured by a CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega). All assays were repeated as independent experiments at least three times.
FDFT1 mRNA quantification in prostate biopsy specimens A transrectal ultrasound-guided prostate needle biopsy was performed according to a method described previously. 22 An additional core was obtained from the peripheral zone very close to the core used for pathological diagnosis to quantify mRNA. Tissue samples were immediately frozen in liquid nitrogen and stored at --80 1C until use. The Gleason scores of the specimens were estimated from the diagnosis of the adjacent positive core. The positive core rates ranged from 44.4 to 100% (average, 78.1%; median, 86.7%) and from 26.7 to 72.7% (average, 57.2%; median, 50.0%) for Gleason scores of 8--10 and a Gleason score of 7, respectively. In the post-androgen deprivation group, samples were obtained from patients treated for 6 months with a luteinizing hormone-releasing hormone agonist. Samples were obtained from patients with a BPH diagnosis as a reference. The clinical characteristics of the prostate cancer and BPH cases are shown in Table 3 . Total RNA extraction, complementary DNA synthesis and quantification of FDFT1 transcript levels were performed by the method described in the proliferation assay part. 
Ethics statement
The ethics committee of Gunma University approved this study. All participants were enrolled after providing written informed consent.
Statistical analyses
An w 2 test was performed to evaluate whether the distribution of the genotype and allele frequencies of the SNPs showed a significant difference between the cases and controls. Crude and age-adjusted odds ratios were calculated as an estimate of relative risk, and 95% confidence intervals were calculated from unconditional logistic regression models. The genotypes were compared between the cases and controls. Student's t-test or analysis of variance was used to analyze the mean proliferation rates or gene expression values. The values were considered significantly different if their P-values were o0.05. SPSS software (SPSS, Chicago, IL, USA) was used.
RESULTS
Association study of FDFT1 SNPs
In the current study, we evaluated five SNPs of FDFT1. Table 2 shows the frequency and odds ratio for each variant in the controls and subjects with FPC. Among the controls, the GG and GA þ AA genotypes of rs2645429 were observed in 57.2% and 42.8% of the subjects, respectively, whereas they were observed in 41.8% and 58.2% of the patients with FPC, respectively. The GA þ AA genotype of rs2645429 was significantly associated with the risk of developing prostate cancer (crude odds ratio, 1.861; 95% confidence interval, 1.101--3.125; P ¼ 0.026; ageadjusted odds ratio, 1.768; 95% confidence interval, 1.043--3.000; P ¼ 0.034). No significant difference was found in the other SNPs: rs11549147, hcv25649966, rs2294136 and rs1804473. When we stratified the cases according to their clinical stages and Gleason scores, no significant difference was observed among the genotypes of rs2645429 (data not shown).
FDFT1 promoter genotypes and promoter activity An association study on FDFT1 showed that the A allele was a risk allele of rs2645429. Rs2645429 is located 6 bp upstream of a putative sterol response element (SRE)-1, and we hypothesized that the activity of the promoter might be altered by the substitution of one base in rs2645429. pHSS1kb-Luc had the AA genotype of rs2645429, and we generated a mutant form, pHSSmutated, which had a GG genotype (Figure 1b ) and performed reporter assays using vectors with various FDFT1 promoters. We first used COS-1 cells because of their very high transfection efficiency. As shown in Figure 1c , 532-Luc and 204-Luc had 18% and 7% of the activity of the full-length construct, respectively. pHSS-mutated showed 22% of the activity of the full-length construct (Po0.001). Similarly, significantly reduced promoter activity was observed for pHSS-mutated in LNCaP cells in comparison with pHSS1kb-Luc (Po0.001), as shown in Figure 1d . These observations suggest that the risk allele of rs264429, the A allele, had increased promoter activity in FDFT1.
Effect of the knockdown of FDFT1 or the squalene synthase inhibitor TAK-475 on prostate cancer proliferation To demonstrate the effect of FDFT1 or its encoded protein, squalene synthase, on prostate cancer cells, we first knocked down FDFT1 using siRNA transfection. FDFT1 siRNA treatment using three different siRNAs inhibited FDFT1 gene expression (Figures 2a and b) and inhibited cell proliferation in both LNCaP and PC-3 cells, as shown in Figures 2c and d . We also performed enzyme inhibition using the squalene synthase inhibitor TAK-475. In LNCaP cells, cell proliferation was significantly inhibited in a dose-dependent manner (Figure 3a) . However, in PC-3 cells, only a high concentration of TAK-475 inhibited cell proliferation (Figure 3b ).
FDFT1 gene expression in prostate biopsy specimens Finally, we quantified the FDFT1 transcript in prostate biopsy specimens. As shown in Table 4 , transcript levels were significantly higher in prostate cancer tissues versus benign tissues, and those in very aggressive cancers (that is, Gleason score 8--10) were significantly higher than those in moderately aggressive (Gleason score 7) cancers. After 6 months of androgen deprivation therapy using a luteinizing hormone-releasing hormone agonist, the FDFT1 transcript levels were similar to those in the BPH samples.
DISCUSSION
In the present study, we first carried out genotyping of five SNPs in FDFT1 among the subjects with FPC; prostatic hyperplasia cases served as controls. We observed that the A allele of rs2645429, which is located in the promoter region of FDFT1, was significantly associated with the risk of prostate cancer in our subjects.
To our knowledge, this is the first report to show an association between FDFT1 polymorphisms and prostate cancer risk. The promoter region of FDFT1 has a 10-bp element, called SRE-1, which mediates the increased transcription of cholesterol biosynthesis genes involving FDFT1 through the binding of SREBP. 23, 24 The SNP rs2645429 exists very close (6 bp upstream) to the SRE-1, and we hypothesized that the A allele of rs2645429 promotes increased FDFT1 transcription.
Next, we conducted promoter reporter assays of FDFT1 to determine the effects of various genotypes of rs2645429 on promoter activity. The GG genotype of rs2645429 had only B25% of the promoter activity observed with the AA genotype. The GG genotype promoter activity was equal to that of pHSS532-Luc and was not lower than the activity of pHSS204-Luc, in which one SRE-1 and two nuclear factor-1 sites were deleted. These findings suggest that the upstream sequence of rs2645429 was associated with differences in pHSS-1kb-LUC and pHSS-mutated promoter activity. Although the mechanism by which the A to G substitution caused a marked change in FDFT1 promoter activity remains to be clarified, it is noteworthy that a common variant in the promoter region affects the transcription level. A SNP analysis of FDFT1 has not been performed in relation to the risk of cancer development or clinical features, although we found three reports that examined the association between FDFT1 SNPs and nonalcoholic fatty liver disease or plasma lipid traits. Do et al. 25 reported that rs11549147 (K45R) was associated with serum total cholesterol levels in a French--Canadian population. Although the K45R substitution was apparently not detrimental to the protein, rs11549147 was suggested to be involved in aberrant exon splicing. Chalasani et al. 26 studied the association of histological features of nonalcoholic fatty liver disease with SNPs related to lipid metabolism. They found that the nonalcoholic fatty acid disease score was significantly related to rs2645424 of FDFT1, located in intron 7. Ballestri et al. 27 reported that the TT genotype of rs2645424 was significantly associated with fibrosis in patients with nonalcoholic fatty liver disease.
FDFT1 encodes squalene synthase that catalyzes the first reaction of the mevalonate/isoprenoid pathway committed exclusively to cholesterol biosynthesis. 28, 29 Thus, squalene synthase plays a key role in directing intermediates to the sterol branch of this metabolic pathway. Brusselmans et al. 16 reported that squalene synthase regulates cellular levels of cholesterol. Cholesterol is known to be important in cancer cell growth, including prostate cancer. Some reports have shown a relationship between malignancy and cholesterol levels in prostatic tissue and secretions 30, 31 and in lipid rafts, which are key platforms for cell signaling events. 32 Statins are known to inhibit prostate cancer cell proliferation, lowering the raft cholesterol content. 33 In this study, prostate cell proliferation was inhibited by FDFT1 siRNA and TAK-475, a squalene synthase inhibitor. This suggests that FDFT1 may play an important role in regulating prostate cancer cell proliferation via the mevalonate/isoprenoid pathway. We also studied the response to squalene synthase inhibition in PC-3 cells and found that the inhibitory response in PC-3 cells was less than that in LNCaP cells. We had previously reported that FDFT1 expression levels in PC-3 cells were approximately one-fortieth of those in LNCaP cells. 17 These differing expression profiles of FDFT1 may affect the response in PC-3 cells. Considering that the risk allele, the FDFT1 AA genotype, showed significantly higher promoter activities, FDFT1 gene expression levels might be higher in patients with the risk allele leading to prostate cancer proliferation.
The aggressiveness of prostate cancer is strongly reflected in Gleason scores. 34 To our knowledge, there is no previous report on an association between aggressiveness and FDFT1 expression in any cancer. We observed significantly higher expression levels of FDFT1 in samples with high Gleason scores in the present study. Hughes et al. 35 studied cathepsin B mRNA expression in esophageal adenocarcinoma. The CTSB gene that encodes cathepsin B is located at 8p22-23, and FDFT1 is located very close to CTSB. FDFT1 was overexpressed by gene amplification of the loci in esophageal adenocarcinoma. Hughes et al. 35 reported that the presence of two potential nuclear factor-1 binding sites, two SREs, two Sp1 promoter elements and one CCAAT box in the promoter region of FDFT1 resulted in mRNA overexpression in the amplified loci.
Swinnen et al. 36--38 studied the androgen dependency of genes involved in lipid metabolism. Regarding cholesterol metabolism, 3-hydroxy-3-methylglutaryl-CoA synthase and reductase, farnesyl diphosphate synthase, 3-b-hydroxysterol-D-24 reductase, lowdensity lipoprotein receptor, SRE-binding protein-1C and -2 and SREEB cleavage-activating protein were reported to be androgen regulated.
A recent study by the same group showed that squalene synthase was also androgen regulated in prostate cancer cell lines. 16 In the present study, we confirmed that FDFT1 expression levels were significantly reduced after 6 months of androgen deprivation therapy in human prostate specimens. Further studies are warranted to confirm the androgen dependency of squalene synthase in the human prostate gland.
Recently, drugs interfering with the mevalonate/isoprenoid pathway 39 such as statins, 40 bisphosphonates 41 and farnesyl pyrophosphate synthase modulator 42 have been studied for their anticancer activities. Furthermore, several clinical studies on statin action in prostate cancer have been reported. Platz et al. 43 reported that the use of statins reduced the risk of advanced prostate cancer. Mondul et al. 44 observed that the use of statins might protect against prostate cancer with poorer pathological characteristics in prostatectomy patients. Furthermore, Kollmeier et al. 45 reported that statin use during high-dose radiation therapy for clinically localized prostate cancer was associated with significant improvement in progression-free survival in high-risk patients.
The present study suggests that interfering with the sterol branch of the mevalonate/isoprenoid pathway using squalene synthase inhibitors may be a candidate novel modality for the treatment/prevention of prostate cancer. Additional studies, including animal studies, are needed to clarify this point.
The limitations of this study were the relatively small number of participants and the clinical characteristics of the enrolled patients in the association study. The distribution of Gleason scores is relatively high in Japan compared with that in the United States. According to the Japanese Prostate Cancer Registry, the rate of Gleason score X7 account for 67% of cases and shows the relatively high prevalence of a high Gleason score. 46 In the present study, most cases had progressive stages, and M1 accounted for 27% of all cases. The high prevalence of Gleason score of X7 in this cohort was attributed to these clinical characteristics. Therefore, a larger-scale analysis is warranted to analyze and confirm the association between the FDFT1 rs2645429 polymorphism and prostate cancer risk to be generalizable to sporadic prostate cancer.
In conclusion, the AA genotype of rs2645429 in FDFT1 increased the promoter activity of the gene and increased the risk of prostate cancer in our FPC pedigrees. FDFT1 was expressed at a significantly higher level in high-grade prostate cancers, and the inhibition of squalene synthase, the enzyme encoded by FDFT1, significantly inhibited prostate cancer cell proliferation. These findings suggest that FDFT1 and its encoded enzyme, squalene synthase, may play an important role in prostate cancer development and its aggressive phenotypes. Abbreviations: ADT, androgen deprivation therapy; FDFT1, farnesyl diphosphate farnesyltransferase; GS, Gleason score; GS7, Gleason score 7; GS8--10, Gleason score 8--10.
